Loading...
XNAS
MDXH
Market cap56mUSD
Jun 16, Last price  
1.99USD
1D
-0.50%
1Q
23.60%
IPO
-83.42%
Name

MDxHealth SA

Chart & Performance

D1W1MN
XNAS:MDXH chart
No data to show
P/E
—
P/S
0.63
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.30%
Rev. gr., 5y
50.19%
Revenues
90m
+28.29%
3,649,1333,657,1683,850,5834,209,7053,650,6393,372,7883,482,5994,918,4017,554,00011,479,00017,467,00029,867,00040,508,00028,338,00011,785,00018,372,00022,239,00037,054,00070,193,00090,049,000
Net income
-38m
L-11.67%
00000000-16,175,000-15,256,000-14,473,000-13,174,000-12,288,000-32,450,000-43,100,000-30,007,000-30,877,000-50,188,000-43,100,000-38,069,000
CFO
-19m
L-13.80%
00000000-14,105,000-18,513,000-14,394,000-16,585,000-10,489,000-28,543,000-22,289,000-20,244,000-22,548,000-34,118,000-21,497,000-18,530,000
Earnings
Aug 14, 2025

Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
URL
https://mdxhealth.com/
IPO date
Jun 26, 2006
Employees
252
Domiciled in
BE
Incorporated in
BE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
90,049
28.29%
70,193
89.43%
37,054
66.62%
Cost of revenue
109,242
92,565
75,513
Unusual Expense (Income)
NOPBT
(19,193)
(22,372)
(38,459)
NOPBT Margin
Operating Taxes
382
1,000
6,144
Tax Rate
NOPAT
(19,575)
(22,373)
(44,603)
Net income
(38,069)
-11.67%
(43,100)
-14.12%
(50,188)
62.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
40,739
39,599
BB yield
Debt
Debt current
1,684
2,123
1,788
Long-term debt
67,153
44,200
42,268
Deferred revenue
Other long-term liabilities
41,445
63,259
53,537
Net debt
21,103
23,180
28,553
Cash flow
Cash from operating activities
(18,530)
(21,497)
(34,118)
CAPEX
(1,188)
(2,747)
(4,163)
Cash from investing activities
(1,636)
(3,931)
(29,163)
Cash from financing activities
44,598
32,280
20,841
FCF
(22,610)
(24,424)
(47,479)
Balance
Cash
46,798
22,380
15,503
Long term investments
936
763
Excess cash
43,232
19,633
13,650
Stockholders' equity
(155,460)
(145,969)
(155,336)
Invested Capital
271,810
257,229
257,981
ROIC
ROCE
EV
Common stock shares outstanding
32,818
25,911
15,866
Price
Market cap
EV
EBITDA
(11,154)
(15,513)
(33,550)
EV/EBITDA
Interest
7,629
5,582
6,144
Interest/NOPBT